Anticholinesterase activity of β-carboline-1,3,5-triazine hybrids

Paula Baréa1, Valéria Aquilino Barbosa1, Diego Alberto dos Santos Yamazaki1, Carla Maria Beraldi Gomes1, Claudio R. Novello2, William Ferreira da Costa1, Gisele de Freitas Gauze1, Maria Helena Sarragiotto1,

1State University of Maringá (UEM), Chemistry Department, PR, Brazil, 2Federal Technological University of Paraná, Department of Chemistry and Biology, Francisco Beltrão-PR, Brazil

INTRODUCTION

Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder (Larson, Kukull, Katzman, 1992), characterised by cognitive impairment, which is associated by means of cholinergic hypothesis, to the loss cholinergic of neurons and a decrease in levels of cholinergic neurotransmission (Francis et al., 1999; Pinto, Lanctôt, Herrmann, 2011). The hydrolysis of the neurotransmitter acetylcholine (ACh) into choline and acetic acid, a reaction catalysed by enzymes of the cholinesterase family, is necessary to allow a cholinergic neuron to return to its resting state after activation (Čolović et al., 2013). The acetylcholinesterase (AChE) predominates in the healthy brain, while the butyrylcholinesterase (BuChE) is considered to play a minor role in the regulation of synaptic ACh levels (Silva et al., 2014). In fact, most of the current drugs used for AD treatment are based on this hypothesis, acting mainly by the inhibition of AChE (Silva et al., 2014; Čolović et al., 2013). However, studies have shown that as AD progresses, the BuChE activity progressively increases, while AChE activity remains unchanged or gradually decreases. When this occurs, the BuChE assumes function of metabolize the ACh in the synapse (Darvesh, Hopkins, Geula, 2003; Anand, Singh, 2013; Li et al., 2017). Thus, also inhibiting BuChE, cognitive improvements associated with the current cholinesterase inhibitors can be obtained. As a result, both AChE and BuChE can be considered as therapeutic targets in Alzheimer’s disease treatment (Darvesh, Hopkins, Geula, 2003; Anand, Singh, 2013; Li et al., 2017).

The treatment of AD usually is performed with cholinesterase inhibitors (donepezil, rivastigmine and galantamine), which enhance cholinergic signalling in the central nervous system and cognitive symptoms. However, these drugs do not prevent the AD progression, and unfortunately there is still no cure for this disease (Silva et al., 2014; Pinto, Lanctôt, Herrmann, 2011; Čolović et al., 2013).

In recent years, several works have been carried out with the aim of obtaining new inhibitors for AChE and BuChE, for the treatment of AD (Anand, Singh, 2013; Li
et al., 2017). In this context, several classes of heterocyclic compounds, including those containing the 1,3,5-triazine and β-carboline nucleus, were described as potential cholinesterase inhibitors (Veloso et al., 2013; Jameel et al., 2017; Maqbool et al., 2016; Rook et al., 2010; Jin-Shuai et al., 2014; Horton et al., 2017).

Studies have demonstrated that 1,3,5-triazine derivatives were found to act as multi-target anti-Alzheimer agents (Veloso et al., 2013; Jameel et al., 2017; Maqbool et al., 2016; Trifunović et al., 2017). Trisubstituted triazines (I, Figure 1), for example, inhibited important targets associated with AD, such as AChE, BuChE and Aβ aggregation (Veloso et al., 2013). The triazine-triazolopyrimidine hybrid II (Figure 1) showed the inhibition of AChE ($IC_{50} = 0.065 \mu M$) and BuChE ($IC_{50} = 1.88 \mu M$) similar to donepezil ($IC_{50} = 0.047 \mu M$ for AChE and 2.72 $\mu M$ for BuChE), which is a potential candidate for anti-Alzheimer’s drug (Jameel et al., 2017). Also, cyanopyridine-triazine hybrids inhibit AChE and BuChE, and can reduce neuronal death induced by $H_2O_2$-mediated oxidative stress and $A\beta_{1-42}$ induced cytotoxicity (Maqbool et al., 2016).

![Figure 1 - Structures of 1,3,5-triazine (I and II) and β-carboline (III, IV and Va,b) derivatives with anticholinesterase activity, of DYRK1A inhibitor VI and of β-carboline-1,3,5-triazine hybrid VII.](image)

Studies focusing on the properties of β-carbolines concerning neurodegenerative diseases have also been intensified in recent years, and several researches have highlighted these alkaloids as a new class of anti-Alzheimer agents. β-Carboline derivatives showed activities in neurological disorders associated with AD, acting as potent inhibitors of AChE and BuChE (Rook et al., 2010; Jin-Shuai et al., 2014; Horton et al., 2017; Torres et al., 2012), dual specificity tyrosine phosphorylation regulated kinase-1A (DYRK1A) (Drung et al., 2014; Rüben et al., 2015) and monoamine oxidase (MAO) (Santillo et al., 2014). The bivalent β-carboline derivative III (Figure 1) showed potent anticholinesterase activity, displaying AChE inhibition ($IC_{50} = 0.5$ nM) higher than the reference drug tacrine ($IC_{50} \approx 45$ nM), and approximately the same activity as that of tacrine for BuChE ($IC_{50} = 5$ nM) (Rook et al., 2010). On the other hand, the harmane (IV, Figure 1) and its β-carbolinium derivatives Va and Vb (Figure 1) exhibited greater selectivity towards BuChE over AChE. The compounds Va and Vb ($IC_{50} = 0.23$ and 0.637 $\mu M$) were more active to BuChE than physostigmine ($IC_{50} = 3.7$ $\mu M$) making them suitable prototypes in the search for anti-Alzheimer drugs (Torres et al., 2012). Also, β-carbolines with an extended aromatic ring system were...
highly active and selective for BuChE, and it was found that over 60% of the studied compounds showed a better inhibitory activity of BuChE than the drug galantamine (Horton et al., 2017).

In our previous work, we investigated the properties of β-carbolines related to neurodegenerative diseases, which led us to identify compound VI (Figure 1) as a potent DYRK1A and MAO-A inhibitor (Drung et al., 2014). By continuing our research, and taking in account the related proprieties of β-carbolines and 1,3,5-triazines, in this work we evaluated the anticholinesterase activity of β-carboline-1,3,5-triazine hybrids VII (Figure 1) against AChE and BuChE. Additionally, kinetic and molecular docking studies were carried out for the most potent compound, aiming to evaluate its inhibition mode against BuChE.

MATERIAL AND METHODS

Synthesis of β-carboline-1,3,5-triazine hydrochlorides (8-13)

The β-carboline-1,3,5-triazine hybrids were synthesised as described for Baréa et al. (2018). The hydrochloride salts 8-13 were prepared from the treatment of β-carboline-1,3,5-triazine hybrids (1 mmol) with hydrochloric acid (12 M) in methanol, at room temperature for 4 h. Compounds 8-13 were obtained in yields in the range from 50–80%. Elemental analysis for compound 12, calculated for C_{23}H_{23}N_{11}O.5HCl: C 42.38, H 4.33, N 23.64, found: C 43.26, H 4.76, N 20.20.

In vitro assays

**In vitro inhibition studies on AChE and BuChE**

AChE (from electrophorus electricus, type VI-S, lyophilised powder, lot 041M7009V), BuChE (from equine serum, lyophilised powder, lot SLBB2114V). 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB, Ellman’s reagent), acetylthiocholine iodide, and S-butyrylthiocholine iodide were purchased from Sigma Aldrich. Absorbance measurements were taken using a Molecular Devices FlexStation 3 Microplate Reader with Softmax Pro 5.3 software.

Anticholinesterase activities of β-carboline-1,3,5-triazine hydrochlorides against AChE and BuChE were evaluated according to Ellman’s modified method (Ellman et al., 1961). Stock solutions of the tested compounds 8-13 were prepared in milli-Q water. The tests were performed in polystyrene 96-well plate, with 125 µL of DTNB (0.5 mM), 50 µL of buffer solution of phosphate (pH 8), 25 µL of sample solution at different concentrations and without the inhibitor (control), and 25 µL of enzyme solution of AChE (0.23 U mL$^{-1}$ prepared in buffer solution of phosphate) or BuChE (0.23 U mL$^{-1}$ prepared in buffer solution of phosphate) were added to each well. The plate was incubated at 30°C for 15 minutes under stirring, and then absorbance was measured at a wavelength of 412 nm. After this time, 25 µL of substrate (acetylthiocholine or butyrylthiocholine, 5 mM, prepared in milli-Q water) was added to each well. The plate was kept at 30°C, under stirring, and the absorbance was measured again at the same wavelength after 4 minutes. The tests were performed in triplicate.

The rates of reactions were calculated using appropriate software (Origin 6.1). The inhibition percentages were calculated by comparing of control reaction rate with the sample reaction rate using Eq.1:

\[
\%\text{inhibition} = \left(\frac{\text{control reaction rate}-\text{sample reaction rate}}{\text{control reaction rate}}\right) \times 100 \tag{1}
\]

The inhibition curve was obtained by plotting an inhibition percentage graph versus the logarithm of the inhibitor concentration.

**Kinetic analysis of BuChE inhibition**

Kinetic studies were carried out by Ellman’s modified method (Ellman et al., 1961) for compound 12, using a 0.23 U mL$^{-1}$ solution of BuChE from equine. The test was performed without the inhibitor, in 0.3 and 3.0 µM concentrations of inhibitor 12 for BuChE. Butyrylthiocholine iodide was used as substrate of the reaction in the following final concentrations: 0.05, 0.125, 0.50, 0.75, 1.0 and 2.0 µM. The absorbance was measured in 10 s for 6 min. The obtained data were used to create substrate-velocity curves which were transformed using the Origin 6.1 program into Linerweaver-Burk plots.
Molecular Modelling

The crystal structure of BuChE complexed with butyrylcholinesterase (code ID: 1P0P) (Nicolet et al., 2003) was obtained from the Protein Data Bank and the \(N\)-\{2-[(4,6-dihydrazinyl-1,3,5-triazin-2-yl)aminoethyl]-1-phenyl-\(\beta\)-carboline-3-carboxamide (12) structure was drawn using the Marvin Sketch Version 14.8.25 ChemAxon. The molecular docking studies were performed using the AutoDock Vina program (Trott, Olson, 2010) implemented at the interface PyRx 0.9 (Wolf, 2009) using default parameters. For each PDB file, some molecules of water and other ligands (except butyrylcholinesterase) were removed. The box dimensions were set at 25 × 22 × 22 Å and the center of the grid box was placed at coordinates \(x = 133.7, y = 115.1, z = 41.0\).

Re-docking simulations were performed to validate the parameters that had been chosen and were repeated four times which gave a RMSD values below 0.5 Å. The best results were submitted to energy minimisation with the NAMD2 program (Phillips et al., 2005). The force field adopted for proteins was CHARMM C35b2-C36a2, and for the ligands, they were generated in the same format as the SwissParam server (Zoete et al., 2011). The results were shown with the CCP4 Molecular Graphics software (McNicholas et al., 2011).

RESULTS AND DISCUSSION

Chemistry

The \(\beta\)-carboline-1,3,5-triazine hybrids 8-13 (Scheme 1) were synthesised as described for Baréa et al. (2018). Briefly, the \(\beta\)-carboline intermediate 1, obtained from \(L\)-tryptophan commercial, was subjected to reaction with cyanuric chloride in the absence or presence of different amines, under basic medium. The hydrochloride salts were prepared from the treatment of compounds 8-13 with hydrochloric acid in methanol (Scheme 1).

**SCHEME 1** - Synthesis of compounds 8-13. Reagents and conditions: (a) Cyanuric chloride, NaOH (1M), H\(_2\)O, CH\(_3\)CN, THF, 0°C, 1 h. (b) 1) Cyanuric chloride, NaOH (1M), H\(_2\)O, CH\(_3\)CN, THF, 0°C, 1 h; 2) Amine (cyclohexylamine for 9; 1-methylpiperazine for 10; benzylamine for 11; hydrate hydrazine for 12; isopropylamine for 13), 70°C, 48 h; (c) MeOH, HCl 12 M, rt., 4 h.
**Anticholinesterase activity**

The anticholinesterase activities of β-carboline-1,3,5-triazine hydrochlorides 8-13 and donepezil (reference compound) were evaluated according to the Ellman method (Ellman et al., 1961). Firstly, the compounds 8-13 were evaluated in vitro at concentrations of 10 µM and 100 µM against AChE and BuChE and their percentages of inhibition were determined (Table I). All compounds showed less than 50% or no inhibition for AChE, and their IC$_{50}$ (50% Inhibitory Concentration) values were not determined for this enzyme. On the other hand, all hybrids inhibited the BuChE at a concentration of 100 µM, showing inhibition percentage in the range from 67.3–91.9%, and most of them also inhibited this enzyme at concentration of 10 µM (40.5–82.7%). Thus, the IC$_{50}$ values were determined for compounds that inhibited more than 40% of this enzyme, at a concentration of 10 µM (Table I). The obtained IC$_{50}$ values ranged from 1.0–18.8 µM, with derivative 12, containing the hydrazinyl group at 6- and 4-positions of 1,3,5-triazine ring, the most active among the tested compounds for BuChE.

In summary, our results show that the analysed β-carboline derivatives were selective to BuChE. This selectivity can be explained based on the volume of the BuChE active site gorge, which is approximately 200 Å$^3$ larger than the AChE gorge (Saxena et al., 1997; Johnson, Moore, 2012; Masson, Carletti, Nachon, 2009), allowing the accommodation of tested β-carboline-1,3,5-triazine hybrids. Moreover, other compounds of the β-carboline class with a flexible linker also exhibited selectivity for BuChE (Zhao et al., 2018). The authors explain that folded molecules are suitable for the relatively spherical and large cavity of BuChE, but not stretched and slender enough to fit the narrow gorge of AChE (Zhao et al., 2018). Therefore, the presence of the flexible N-aminoethyl-carboxamide group between the β-carboline and 1,3,5-triazine moieties in 8-13 probably corroborated the obtained selectivity.

**TABLE I** - Inhibition percentages of compounds 8-13 against AChE and BuChE and their IC$_{50}$ values for BuChE

| Comp. | R  | % inhibition AChE | % inhibition BuChE | BuChE IC$_{50}$ (µM) |
|-------|----|-------------------|-------------------|---------------------|
|       | 8  | CI                | NI                | 10.2 ± 0.3          |
|       | 9  | NH               | NI                | N.D.                |
| 10    | H$_3$C-N N^+ | NI                | 45.9 ± 2.8        | 83.4 ± 1.6          | 12.0 ± 1.4 |
| 11    | N^+ | NI                | 49.3 ± 5.4        | 83.0 ± 2.2          | 18.8 ± 3.8 |
| 12    | NHNH$_2$ | 7.6 ± 0.2        | 29.2 ± 6.5        | 91.9 ± 5.5          | 1.0 ± 0.1  |
| 13    | N^+ | 9.7 ± 3.3        | 17.1 ± 1.5        | 80.1 ± 6.2          | 5.8 ± 4.1  |

NI = No Inhibition. ND = Not Determined. Donepezil was used as positive control (IC$_{50}$ AChE = 10.8 ± 3.0 nM; IC$_{50}$ BuChE = 2.9 ± 0.5 µM).
Enzyme kinetics

Due to the potent activity observed for compound \(N\)-\{2-[(4,6-dihyrazinyl-1,3,5-triazin-2-yl)amino]ethyl\}-1-phenyl-\(\beta\)-carboline-3-carboxamide (12), this compound was submitted to kinetics studies to investigate its type of BuChE inhibition. The kinetics studies were performed using the modified Ellman’s method (Ellman et al., 1961). To assess the kinetic parameters, we measured the initial rate of enzyme activity at different concentrations of substrate butyrylthiocholine (0.05 to 2.0 mM) in the absence and presence of the compound 12. Lineweaver-Burk plots (Figure 2) were generated by plotting the reciprocal of the initial rate \(1/V_0\) against the reciprocal of substrate concentrations \(1/[S]\) for the different concentrations of 12, resulting from the substrate–velocity curves for BuChE.

![Graphical analysis of Lineweaver-Burk plots](image)

**FIGURE 2** - Lineweaver-Burk plot for the inhibition of BuChE with different butyrylthiocholine concentrations (0.05 to 2.0 mM) in the absence and presence of compound 12 at concentrations of 0.3 and 3.0 µM.

Graphical analysis of Lineweaver-Burk plots (Figure 2) and the kinetic parameters of BuChE activity showed a practically unchanged \(V_{\max}\) value \((V_{\max} = 0.11, 0.10\) and 0.11 µMs\(^{-1}\) in the absence and presence of 0.3 and 3.0 µM of 12, respectively) and an increasing \(K_m\) value \((K_m = 0.28, 0.30\) and 1.58 mM in the absence and presence of 0.3 and 3.0 µM of 12, respectively) with increasing inhibitor concentrations, i.e. increasing slopes and the same intercepts on the y-axis \((-1/V_{\max})\). This pattern indicates a competitive type of inhibition (Copeland, 2000). It is shown that compound 12 and substrate (butyrylthiocholine) compete for the same active site, i.e. the inhibitor interacts with the same binding site as the substrate.

For hybrid 12, the dissociation constant \(K_i\) value obtained was 0.55 µM while the \(K_m\) value of butyrylthiocholine iodide for BuChE was 0.28 mM, which shows that the binding capacity of 12 with BuChE is approximately 509-fold that of the substrate. In addition, the hybrid 12 exhibited a \(K_i\) value similar to derivative Vb (Figure 1, \(K_i = 0.64\) µM for BuChE) (Torres et al., 2012) and showed a binding capacity that was approximately 164-fold greater than that of harmane (IV, Figure 1, \(K_i = 90\) µM for BuChE) (Torres et al., 2012).

Molecular modelling studies

The molecular docking calculations were performed using AutoDockVina program (Trott, Olson, 2010) implemented at the interface PyRx 0.9 (Wolf, 2009). Compound 12 was docked in the active site of BuChE (PDB: 1P0P) (Nicolet et al., 2003) derived from the
Anticholinesterase activity of β-caroline-1,3,5-triazine hybrids

complex of the enzymes with butyrylcholinesterase obtained from the Protein Data Bank (PDB). The best docked poses, i.e. the lowest energy conformer in the most populated cluster of conformers, were subjected to energy minimisation by NAMD (Phillips et al., 2005) program and analysed to explain interactions between ligands and the target enzyme. Figure 3 shows that compound 12 is oriented in active site gorge of BuChE. The hydrogen atom of protonated triazine moieties interacts with the carboxylate oxygen atom of Gly115 via an H-bond. The oxygen atom of the carbonyl group forms an H-bond with OH group of Thr120 and NH group also forms an H-bond with the carboxylate oxygen atom of Gly116. The protonated nitrogen of hydrazine moieties interacts with Tyr440 and Trp82 by π-cation interaction. Both hydrogen atoms of the protonated hydrazine moieties are therefore likely to form an H-bond with the carboxylate oxygen atoms of His438 and Gly439 and the other protonated hydrazine moieties also interact with Glu197 by H-bond interactions. This strong interaction with His438 (residue of the catalytic triad) (Nicolet et al., 2003) and the π-cation interaction with Trp82 (residue of catalytic anionic site) (Nicolet et al., 2003) confirm that the compound competes with the same binding site of the butyrylthiocholine.

FIGURE 3 - Binding mode of 12 and BuChE. The compound is rendered in green ball-and-stick models, and the residues are rendered in grey coloured sticks.

CONCLUSION

In conclusion, we evaluated the anticholinesterase activity of the β-caroline-1,3,5-triazine hybrids against AChE and BuChE. All of the compounds showed significant activity and selectivity for BuChE. The kinetics and molecular docking studies for the most active hybrid 12 indicate that this compound inhibited BuChE via a competitive type of inhibition.

ACKNOWLEDGMENTS

This work was supported by Fundação Araucária, PR, Brazil (Sarragiotto MH, No. 2/2017 Prot. 47223 FA/UEM). We thank CAPES for fellowship (Baréa P) and Complexo de Centrais de Apoio à Pesquisa of Universidade Estadual de Maringá (COMCAP-UEM) for the facilities.

REFERENCES

Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res. 2013;36(4):375-399.

Baréa P, Barbosa VA, Bidóia DL, Carreira de Paula J, Stefanello TF, Ferreira da Costa W, et al. Synthesis, antileishmanial activity and mechanism of action studies of novel β-carbolines as DYRK1A inhibitors. Eur J Med Chem. 2018;150:579-590.

Čolović MB, Kristić DZ, Lazarević-Pašti TD. Bondžić AM, Vasić VM. Acetylcholinesterase inhibitors: Pharmacology and toxicology. Curr Neuropharmacol. 2013;11(3):315-335.

Copeland RA. Enzymes: A Practical Introduction to Structure Mechanism, and Data Analysis. 2nd ed., New York, John Wiley and Sons Inc; 2000.

Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci. 2003;4(2):131-138.

Druge B,Scholz C, Barbosa VA, Nazari A, Sarragiotto MH, Schmidt B. Computational & experimental evaluation of 
structure/activity relationship of β-carbolines as DYRK1A inhibitors. Bioorg Med Chem Lett. 2014;24(20):4854.

Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961;7(2):88.

Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66(2):137-47.

Horton W, Sood A, Peerrannavar S, Kugyela N, Kulkarni A, Tulsan R, et al. Synthesis and application of β-carbolines as novel multi-functional anti-Alzheimer’s disease agents. Bioorg Med Chem Lett. 2017;27(2):232-236.
biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents. Eur J Med Chem. 2017;136:36-51.

Jin-Shuai L, Sai-Sai X, Su-Yi L, Long-Fei P, Xiao-Bing W, Ling-Yi K. Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer’s disease. Bioorg Med Chem. 2014;22(21):6089-6104.

Johnson G, Moore SW. Why has butyrylcholinesterase been retained? Structural and functional diversification in a duplicated gene. Neurochem Int. 2012;61(5):783-797.

Larson EB, Kukull WA, Katzman L. Cognitive Impairment: Dementia and Alzheimer’s Disease. Annu Rev Public Health. 1992;13:431-49.

Li Q, Yang H, Chen Y, Sun H. Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer’s disease. Eur J Med Chem. 2017;132:294-309.

Maqbool M, Manral A, Jameel E, Kumar J, Saini V, Shandilya A, et al. Development of cyanopyridine-triazine hybrids as lead multitarget anti-Alzheimer agents. Bioorg Med Chem. 2016;24(12):2777–2788.

Marvin Sketch Version 14.8.25, 2014, ChemAxon (http://www.chemaxon.com).

McNicholas S, Potterson E, Wilson KS, Noble MEM. Presenting your structures: the CCP4mg molecular-graphics software. Acta Crystallogr. 2011;67(Pt 4):386-394.

Masson P, Carletti E, Nachon F. Structure, activities and biomedical applications of human butyrylcholinesterase. Protein Peptide Lett. 2009;16(10):1215-1224.

Nicolet Y, Lockridge O, Masson P, Fontecilla-camps JC, Nachon F. Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products. J Biol Chem. 2003;278(42):41441-41447.

Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26(16):1781–1802.

Pinto T, Lanctôt KL, Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer’s type. Ageing Res Rev. 2011;10(4):404-412.

Rook Y, Schmidtke K, Gaube F, Schepmann D, Wünch B, Heilmann J, et al. Bivalent β-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010;53(9):3611.

Rüben K, Wurzlbauer A, Walte A, Sippl W, Bracher F, Becker W. Selectivity profiling and biological activity of novel β-carbolines as potent and selective DYRK1 Kinase inhibitors. Plos One. 2015;10(7):1-18.

Santillo MF, Liu Y, Ferguson M, Vohra SN, Wiesenfeld PL. Inhibition of monoamine oxidase (MAO) by β-carbolines and their interactions in live neuronal (PC12) and liver (HuH-7 and MH1C1) cells. Toxicol In Vitro. 2014;28(3):403-410.

Saxena A, Redman AMG, Jiang X, Lockridge O, Doctor BP. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry. 1997;36(48):14642-14651.

Silva T, Reis J, Teixeira J, Borges F. Alzheimer’s disease, enzyme targets and drug discovery struggles: From natural products to drug prototypes. Ageing Res Rev. 2014;15:116-145.

Torres JM, Lira AF, Silva DR, Guzzo LM, Sant’anna CMR, Kümmerle AE, et al. Phytochemistry structural insights into cholinesterases inhibition by harmane β-carbolinium derivatives: A kinetics–molecular modeling approach. Phytchemistry. 2012;81:24-30.

Trifunović J, Borčić V, Vukmirović S, Mikov M. Assessment of the pharmacokinetic profile of novel s-triazine derivatives and their potential use in treatment of Alzheimer’s disease. Life Sci. 2017;168:1-6.

Trott O, Olson AJ. AutoDockVina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem. 2010;31(2):455-461.

Veloso AJ, Dhar D, Chow AM, Zhang B, Tang DWF, Ganesh HVS, et al. sym-Triazines for directed Multitarget modulation of cholinesterases and amyloid-β in Alzheimer’s Disease. ACS Chem Neurosci. 2013;4(2):339-349.

Wolf LK. New software and websites for the chemical enterprise. Chem Eng News, 2009;87:48.

Zhao Y, Ye F, Xu J, Liao Q, Chen L, Zhang W, et al. Design, synthesis and evaluation of novel bivalent β-carboline derivatives as multifuncional agents for the treatment of Alzheimer’s disease. Bioorg Med Chem. 2018;26(13):3812-3824.

Zoete V, Cuenod MA, Grosdidier A, Michielin O. SwissParam: a fast force field generation tool for small organic molecules. J Comput Chem. 2011;32(11):2359.

Received for publication on 20th November 2019
Accepted for publication on 31st March 2020